Hasan FM, Alsahli M, Gerich JE. SGLT2 inhibitors in the treatment of type 2 diabetes. Diabetes Res Clin Pract. 2014;104(3):297–322.
CAS
PubMed
Article
Google Scholar
Scheen AJ. Pharmacodynamics, efficacy and safety of sodium–glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Drugs. 2015;75(1):33–59.
CAS
PubMed
Article
Google Scholar
American Diabetes Association. Standards of medical care in diabetes—2018. Diabetes Care. 2018;41[Suppl 1]:S1–2.
Google Scholar
Dagogo-Jack S, Liu J, Eldor R, et al. Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: The VERTIS SITA2 placebo-controlled randomized study. Diabetes Obes Metab. 2017;20(3):530–40.
PubMed
PubMed Central
Article
Google Scholar
Hollander P, Liu J, Hill J, et al. Ertugliflozin compared with glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin: the VERTIS SU randomized study. Diabetes Ther. 2018;9(1):193–207.
CAS
PubMed
Article
Google Scholar
Pratley RE, Eldor R, Raji A, et al. Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial. Diabetes Obes Metab. 2018;20(5):1111–20.
CAS
PubMed
PubMed Central
Article
Google Scholar
Rosenstock J, Frias J, Páll D, et al. Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET). Diabetes Obes Metab. 2018;20(3):520–9.
CAS
PubMed
Article
Google Scholar
Terra SG, Focht K, Davies M, et al. Phase III, efficacy and safety study of ertugliflozin monotherapy in people with type 2 diabetes mellitus inadequately controlled with diet and exercise alone. Diabetes Obes Metab. 2017;19(5):721–8.
CAS
PubMed
Article
Google Scholar
Qian D, Zhang T, Zheng P, et al. Comparison of oral antidiabetic drugs as add-on treatments in patients with type 2 diabetes uncontrolled on metformin: a network meta-analysis. Diabetes Ther. 2018;9(5):1945–48.
CAS
PubMed
PubMed Central
Article
Google Scholar
Tonin FS, Rotta I, Mendes AM, Pontarolo R. Network meta-analysis: a technique to gather evidence from direct and indirect comparisons. Pharm Pract (Granada). 2017;15(1):943.
PubMed
PubMed Central
Article
Google Scholar
Shyangdan DS, Uthman OA, Waugh N. SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysis. BMJ Open. 2016;6(2):e009417.
PubMed
PubMed Central
Article
Google Scholar
Mearns ES, Sobieraj DM, White CM, et al. Comparative efficacy and safety of antidiabetic drug regimens added to metformin monotherapy in patients with type 2 diabetes: a network meta-analysis. PLoS One. 2015;10(4):e0125879.
PubMed
PubMed Central
Article
Google Scholar
Hoaglin DC, Hawkins N, Jansen JP, et al. Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR task force on indirect treatment comparisons good research practices: part 2. Value Health. 2011;14(4):429–37.
PubMed
Article
Google Scholar
Higgins J, Green S. Cochrane handbook for systematic reviews of interventions. Version 5.1. The Cochrane Collaboration. 2015; https://training.cochrane.org/handbook. Accessed 5 Nov 2018.
Jansen JP, Fleurence R, Devine B, et al. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR task force on indirect treatment comparisons good research practices: part 1. Value Health. 2011;14(4):417–28.
PubMed
Article
Google Scholar
Tacconelli E. Systematic reviews: CRD’s guidance for undertaking reviews in health care. Lancet Infect Dis. 2010;10(4):226.
Article
Google Scholar
Cope S, Zhang J, Saletan S, Smiechowski B, Jansen JP, Schmid P. A process for assessing the feasibility of a network meta-analysis: a case study of everolimus in combination with hormonal therapy versus chemotherapy for advanced breast cancer. BMC Med. 2014;12(1):93.
PubMed
PubMed Central
Article
Google Scholar
Lunn DJ, Thomas A, Best N, Spiegelhalter D. WinBUGS—a Bayesian modelling framework: concepts, structure, and extensibility. Stat Comput. 2000;10(4):325–37.
Article
Google Scholar
Dias S, Sutton AJ, Ades A, Welton NJ. Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials. Med Decis Making. 2013;33(5):607–17.
PubMed
PubMed Central
Article
Google Scholar
Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol. 1997;50(6):683–91.
CAS
PubMed
Article
Google Scholar
Higgins J, Jackson D, Barrett J, Lu G, Ades A, White I. Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies. Res Synth Methods. 2012;3(2):98–110.
CAS
PubMed
PubMed Central
Article
Google Scholar
Kaku K, Kiyosue A, Inoue S, et al. Efficacy and safety of dapagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise. Diabetes Obes Metab. 2014;16(11):1102–10.
CAS
PubMed
Article
Google Scholar
Zaccardi F, Webb D, Htike Z, Youssef D, Khunti K, Davies M. Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis. Diabetes Obes Metab. 2016;18(8):783–94.
CAS
PubMed
Article
Google Scholar
Johnston R, Uthman O, Cummins E, et al. Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation. Health Technol Assess. 2017;21(2):1–218.
PubMed
PubMed Central
Article
Google Scholar
Hadjadj S, Rosenstock J, Meinicke T, Woerle HJ, Broedl UC. Initial combination of empagliflozin and metformin in patients with type 2 diabetes. Diabetes Care. 2016;39(10):1718–28.
CAS
PubMed
Article
Google Scholar
Lewin A, DeFronzo RA, Patel S, et al. Initial combination of empagliflozin and linagliptin in subjects with type 2 diabetes. Diabetes Care. 2015;38(3):394–402.
CAS
PubMed
Article
Google Scholar
Rosenstock J, Chuck L, González-Ortiz M, et al. Initial combination therapy with canagliflozin plus metformin versus each component as monotherapy for drug-naïve type 2 diabetes. Diabetes Care. 2016;39(3):353–62.
PubMed
Article
Google Scholar
Merck & Co Inc., Pfizer Inc. Clinical study report 005: A phase 3, randomized, double-blind, multicenter study to evaluate the efficacy and safety of the combination of ertugliflozin (MK-8835/PF-04971729) with sitagliptin compared with ertugliflozin alone and sitagliptin alone, in the treatment of subjects with T2DM with inadequate glycemic control on metformin monotherapy (VERTIS FACTORIAL). Clinical study report 005: VERTIS FACTORIAL. Merck & Co Inc./Pfizer Inc., New York/New York. 2016.
DeFronzo RA, Lewin A, Patel S, et al. Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin. Diabetes Care. 2015;38(3):384–93.
CAS
PubMed
Article
Google Scholar
Bailey TS, Takacs R, Tinahones FJ, et al. Efficacy and safety of switching from sitagliptin to liraglutide in subjects with type 2 diabetes (LIRA-SWITCH): a randomized, double-blind, double-dummy, active-controlled 26-week trial. Diabetes Obes Metab. 2016;18(12):1191–8.
CAS
PubMed
PubMed Central
Article
Google Scholar
Inagaki N, Kondo K, Yoshinari T, Takahashi N, Susuta Y, Kuki H. Efficacy and safety of canagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled with diet and exercise: a 24-week, randomized, double-blind, placebo-controlled, phase III study. Expert Opin Pharmacother. 2014;15(11):1501–15.
CAS
PubMed
Article
Google Scholar
Ji L, Ma J, Li H, et al. Dapagliflozin as monotherapy in drug-naive Asian patients with type 2 diabetes mellitus: a randomized, blinded, prospective phase III study. Clin Ther. 2014;36(1):84–100.
CAS
PubMed
Article
Google Scholar
Stenlöf K, Cefalu W, Kim KA, et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab. 2013;15(4):372–82.
PubMed
PubMed Central
Article
Google Scholar
Yang W, Han P, Min KW, et al. Efficacy and safety of dapagliflozin in Asian patients with type 2 diabetes after metformin failure: a randomized controlled trial. J Diabetes. 2016;8(6):796–808.
CAS
PubMed
Article
Google Scholar
Rodbard H, Seufert J, Aggarwal N, et al. Efficacy and safety of titrated canagliflozin in patients with type 2 diabetes mellitus inadequately controlled on metformin and sitagliptin. Diabetes Obes Metab. 2016;18(8):812–9.
CAS
PubMed
PubMed Central
Article
Google Scholar
US Food and Drug Administration. STEGLATRO™ (ertugliflozin) prescribing information. 2017, p 11. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209803Orig1s000lbl.pdf. Accessed 5 Nov 2018.
European Medicines Agency. Forxiga summary of product information. 2018, p 47. https://www.ema.europa.eu/documents/assessment-report/forxiga-epar-public-assessment-report_en.pdf. Accessed 5 Nov 2018.
Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–28.
CAS
PubMed
Article
Google Scholar
Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644–57.
CAS
PubMed
Article
Google Scholar
Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. New Engl J Med. 2018. https://www.nejm.org/doi/full/10.1056/NEJMoa1812389. Accessed 18 Jan 2018.
Cannon CP, McGuire DK, Pratley R, et al. Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and safety CardioVascular outcomes trial (VERTIS-CV). Am Heart J. 2018;206:11–23.
CAS
PubMed
Article
Google Scholar
Bailey C, Iqbal N, T’joen C, List J. Dapagliflozin monotherapy in drug-naïve patients with diabetes: a randomized-controlled trial of low-dose range. Diabetes Obes Metab. 2012;14(10):951–9.
CAS
PubMed
Article
Google Scholar
Ferrannini E, Ramos SJ, Salsali A, Tang W, List JF. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care. 2010;33(10):2217–24.
PubMed
PubMed Central
Article
Google Scholar
Roden M, Weng J, Eilbracht J, et al. Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 2013;1(3):208–19.
CAS
PubMed
Article
Google Scholar
Merck & Co Inc., Pfizer Inc. Clinical study report 003: a phase 3, randomized, double-blind, placebo-controlled, 26-week multicenter study with a 26-week extension to evaluate the efficacy and safety of ertugliflozin monotherapy in the treatment of subjects with type 2 diabetes mellitus and inadequate glycemic control despite diet and exercise (VERTIS MET). Clinical study report 003: VERTIS MET. Merck & Co Inc./Pfizer Inc., New York/New York. 2016.
Bailey CJ, Gross JL, Pieters A, Bastien A, List JF. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;375(9733):2223–33.
CAS
PubMed
Article
Google Scholar
Häring H-U, Merker L, Seewaldt-Becker E, et al. Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care. 2014;37(6):1650–9.
PubMed
Article
Google Scholar
Lavalle-González F, Januszewicz A, Davidson J, et al. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia. 2013;56(12):2582–92.
PubMed
PubMed Central
Article
Google Scholar
Merck & Co Inc., Pfizer Inc. Clinical study report 007: a phase 3, randomized, double-blind, placebo-controlled, 26-week multicenter study with a 78-week extension to evaluate the efficacy and safety of ertugliflozin in subjects with type 2 diabetes mellitus and inadequate glycemic control on metformin monotherapy (VERTIS MET). Clinical study report 007: VERTIS MET. Merck & Co Inc./Pfizer Inc., New York/New York. 2016.
Jabbour S, Hardy E, Sugg J, Parikh S. Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study. Diabetes Care. 2014;37(3):740–50.
CAS
PubMed
Article
Google Scholar
Mathieu C, Ranetti AE, Li D, et al. Randomized, double-blind, phase 3 trial of triple therapy with dapagliflozin add-on to saxagliptin plus metformin in type 2 diabetes. Diabetes Care. 2015;38(11):2009–17.
CAS
PubMed
Article
Google Scholar
Søfteland E, Meier JJ, Vangen B, Toorawa R, Maldonado-Lutomirsky M, Broedl UC. Empagliflozin as add-on therapy in patients with type 2 diabetes inadequately controlled with linagliptin and metformin: a 24-week randomized, double-blind, parallel-group trial. Diabetes Care. 2017;40(2):201–9.
PubMed
Article
Google Scholar
Merck & Co Inc., Pfizer Inc. Clinical study report 006: a phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group clinical trial to evaluate the safety and efficacy of ertugliflozin (MK-8835/PF-04971729) in the treatment of subjects with type 2 diabetes mellitus who have inadequate glycemic control on metformin and sitagliptin (VERTIS SITA2). Clinical study report 006: VERTIS SITA2. Merck & Co Inc./Pfizer Inc., New York/New York.2016.